EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression






Transplantation Proceedings 32(7): 2543-2543

Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression



Accession: 047237222

PMID: 11120285

DOI: 10.1016/s0041-1345(00)01783-8



Related references

Liu, B.; Lin, Z.B.; Ming, C.S.; Zhang, W.J.; Chen, Z.S.; Sha, B.; Zeng, F.J.; Chen, S., 2003: Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function. Transplantation Proceedings 35(1): 87-88

Kocak, H.; Yakupoglu, U.; Karatas, G.Uslu.; Yavuz, A.; Gurkan, A.; Erdogan, O.; Ersoy, F.F.; Yakupoglu, G.; Demirbas, A.; Tuncer, M., 2005: Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose. Objectives. Mycophenolate mofetil (MMF) has become more widely prescribed in recent years, but its adverse effects on the gastrointestinal system and bone marrow restrict its use in certain settings. The aim of this study was to compare the demogr...

Yoshida, E.M.; Marotta, P.J.; Greig, P.D.; Kneteman, N.M.; Marleau, D.; Cantarovich, M.; Peltekian, K.M.; Lilly, L.B.; Scudamore, C.H.; Bain, V.G.; Wall, W.J.; Roy, A.; Balshaw, R.F.; Barkun, J.S.T., 2005: Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Posttransplant chronic renal failure, secondary to calcineurin inhibitor agents, is emerging as a major problem in liver transplantation. We report a randomized clinical trial comparing daclizumab, delayed low-dose tacrolimus (target trough level...

Roth, D.; Colona, J.; Burke, G.W.; Ciancio, G.; Esquenazi, V.; Miller, J., 1998: Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Background. Studies using tacrolimus and corticosteroids or the combination of cyclosporine, mycophenolate mofetil, and corticosteroids have been shown to reduce the incidence of biopsy-proven acute rejection episodes in cadaveric kidney recipient...

Yeung, S.; Tsang, W.K.; Tong, K.L.; Wong, S.H.; Lee, W.; Tang, H.L.; Chan, H.W.H.; Chan, A.Y.W., 2004: Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. Both tacrolimus and mycophenolate mofetil (MMF) are potent immunosuppressive agents used in combination for prevention of acute rejection in renal transplantation. We studied the efficacy and safety of tacrolimus/MMF-based primary immunosuppressio...

Morales, J.M.; Andrés, A.; Morales, E.; Herrero, J.C.; Cubas, A.; Praga, M.; Hernández, E.; Ortuño, T.; Dominguez-Gil, B.; Carreño, A.; Delgado, M.; Manzanares, C., 1999: Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid. Transplantation Proceedings 31(7a): 75s-77s

Müller, H.; Solari, S.; Zuñiga, C.; Pedreros, C.; Troncoso, J.; Morente, C.; Ovalle, R.; Acosta, P.; Chavez, T.; Albornoz, E., 2008: Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. The association of tacrolimus (TAC) and mycophenolate mofetil (MMF) in renal transplant patients has diminished the incidence of acute rejection. We evaluated the use of generic TAC and MMF as primary immunosuppression in 6 living related (LR) an...

Smith, L.D.; Somerville, K.T.oy; Holman, J.; Sherbotie, J., 2003: Corticosteroid minimization in pediatric renal transplant recipients under thymoglobulin, tacrolimus and mycophenolate mofetil immunosuppression. Journal of the American Society of Nephrology 14(Abstracts Issue): 647A, November

Teebken, O.E.; Strüber, M.; Harringer, W.; Pichlmaier, M.A.; Haverich, A., 2002: Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. Transplantation Proceedings 34(4): 1265-1268

Ciancio, G.; Burke, G.W.; Suzart, K.; Roth, D.; Kupin, W.; Rosen, A.; Olson, L.; Esquenazi, V.; Miller, J., 2002: Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Background: Recent reports have demonstrated the efficacy of interleukin-2-receptor blockers in lowering the incidence of early acute rejection in cyclosporine-treated kidney recipients when compared to patients not induced with an antibody produc...